Roquinimex (Linomide, PNU212616, ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity, inhibits angiogenesis and reduces the secretion of TNF alpha. IC50 value: Target: TNF alpha Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3].
Molekulargewicht:
308.33
Reinheit:
99.69
CAS Nummer:
[84088-42-6]
Formel:
C18H16N2O3
Target-Kategorie:
TNF Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
